RBMS1 and neoplasm: To further validate the combinatorial effect of RBMS1 depletion and CTLA4 blockade, we analyzed tumor tissues by an IHC assay and found the combination therapy with RBMS1-depletion and anti-CTLA4 antibody significantly promoted the infiltration of CD8+ T cells as compared to the application of CTLA4 blockade only (Fig. 7H).